Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
5/19/22 | Zealand Pharma (ZEAL) | Zegalogue for Hyperinsulinemia/Hypoglycemia | Subscribers Only | Subscribers Only | Subscribers Only |
5/18/22 | Enanta Pharmaceuticals (ENTA) | EDP-938 for Respiratory Syncytial Virus (RSV) Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
5/16/22 | Bristol Myers Squibb (BMY) | Opdivo for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
5/13/22 | UCB (UCB) | Bimzelx for Psoriasis | Subscribers Only | Subscribers Only | Subscribers Only |
5/12/22 | Bristol Myers Squibb (BMY) | Deucravacitinib for Psoriasis | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/19/22 | Subscribers Only | Subscribers Only | Regulatory - PDUFA for sNDA/sBLA |
03/31/22 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
05/12/22 | Subscribers Only | Subscribers Only | Trial Data - Other |
05/12/22 | Subscribers Only | Subscribers Only | Trial Data - Other |
05/12/22 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |